Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTENT: immunogenicity in patients failing response on anti-TNF
NL-OMON43571Phase 4Recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Feb 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of infliximab, adalimumab, etanercept, golimumab and certolizumab pegol in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and 1 more (2 cohorts), sponsored by Jan van Breemen Institute. Primary endpoints: Phase 1 anti-drug antibody positivity, Phase 2 rheumatoid arthritis efficacy and 4 more. Started Feb 2015; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)psoriasis
Beyond the preview
Go deeper on NL-OMON43571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43571.